Akademik Veri Yönetim Sistemi
6th European Congress of Pharmacology, Granada, Nikaragua, 17 - 20 Temmuz 2012, ss.243-246
Agomelatine, acts as an agonist of melatonergic MT1 and MT2 receptors and as an antagonist of 5-HT2C receptors (Millan et al., 2003). The present study was undertaken to investigate whether chronic agomelatine treatment would block unpredictable chronic mild stress-induced depression-like behavior in mice compared to fluoxetine and endogenous melatonergic agonist melatonin. Results:(1) Agomelatine, significantly reversed the ucms-induced degradation in the coat state; the magnitude was comparable to melatonin and fluoxetine (2) All drugs tested blocked the stress-induced deficit in total number of grooming in splash test, decreased the attack frequency in resident intruder test, reduced the immobility time in tail suspension test and forced swimming test (3) All drugs decreased enhanced levels of plasma acth, il-6 and Tnf-alpha levels in stressed mice. Results of this study support the assumption that agomelatine, with a novel mode of action and a favourable clinical safety and tolerability profile is effective as much as fluoxetine for the treatment of depression.